TESARO is an oncology-focused biopharmaceutical company.
TESARO is dedicated to improving the lives of cancer patients by developing and providing safer and more effective therapeutics and supportive care products.
Contact
TESARO Bio GmbH.
Poststrasse 6
6300 ZUG
Switzerland
| www.tesarobio.com
|
Carolin Hillebrand, country manager of Neurim Pharmaceuticals Switzerland, a neuroscience specialty company, discusses the launch of their lead product Circadin, the only IP-protected product providing a prolonged release formulation of…
CEO of Biomed, Dr. Thomas F. Szuran discusses the keys to success for pharma SMEs and the importance of relationship management, investments, and a culture of internal dialogue. Could you…
Walter Steinlin describes the Federal Commission of Technology and Innovation as a catalyst for turning research into innovation. Based in Bern, Switzerland, the commission funds research institutes in corporate projects,…
Jean-Daniel Gerber, chairman of the board at SIFEM, explains why job creation should be the focus of DFIs (Development Finance Institutions) such as SIFEM; how ESG, environmental, social and governance…
Ronald Scott, CEO of Basilea, a biotech company that was spun out of Roche in 2000, talks about launching its first two products, Zevtera and Cresemba; the milestone agreement with…
Actelion’s global CEO and co-founder, Dr Jean-Paul Clozel, discusses diversifying the company’s portfolio, prioritizing internal research over inorganic acquisitions, and retaining a spirit of independence and innovation during a period…
André Lüscher of Gilead Switzerland, reveals how the case of Sovaldi demonstrates the challenges for a healthcare system to handle a truly disruptive medical innovation, the knock-on effect on Gilead´s…
Andreas Bosshard of Mepha-Teva in Switzerland describes Switzerland’s unique generics market, the quality of the Mepha-Teva brand, innovations within generics, and the company’s growth strategy within the Swiss market. It…
Franz Saladin details the unique scope and operations of the Basel Chamber of Commerce, the history of pharmaceuticals in Basel, and the importance of continuously developing the industry within the…
Biologics giant Biogen is investing USD one billion in a next-generation manufacturing facility in Luterbach, near Solothurn, Switzerland, tripling production capacity and creating 400 new jobs. The decision to situate…
MD Natascha Schill discusses the growing importance and commitment that Biogen has to Switzerland, including a USD one billion investment in new facilities and the creation of 400 jobs in…
Pascal Strupler of the Federal Office of Public Health discusses the intricacies of the Swiss healthcare system, highlighting the importance of the NCD in health prevention, strategies for cost reduction,…
See our Cookie Privacy Policy Here
